Filing Flows › Cardiff Oncology (CRDF) › Stock forecast & fair value
Cardiff Oncology (CRDF) stock forecast and price target
Cardiff Oncology (CRDF) trades at $0.80. 6 analysts' median price target is $6.75 (+749%), from $1.20 to $12.00.
Cardiff Oncology's latest quarter
Cardiff Oncology, Q2 2026: revenue $104K (-14% year over year), net loss $9.2M, operating cash flow −$11.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for CRDF stock?
The median of 6 analysts' 12-month targets is $6.75, +749% from $0.80; the range is $1.20 to $12.00. The average rating is none.
Does Cardiff Oncology usually beat earnings estimates?
It beat the consensus EPS estimate in 75% of the quarters on record.
Is CRDF stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.